Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESSO 45 | How AXSANA is reshaping axillary staging after neoadjuvant therapy

Thorsten Kühn, MD, PhD, Universitätsklinikum Ulm, Ulm, Germany, comments on findings from the AXSANA (NCT04373655) study demonstrating that sentinel lymph node biopsy (SLNB) and targeted axillary dissection (TAD) maintain consistent sensitivity and accuracy across tumor subtypes in breast cancer, and that nodal pathologic complete response rates depend on tumor biology rather than initial nodal burden. Patients with any nodal stage can undergo less invasive axillary staging procedures if they convert to node negativity after neoadjuvant therapy, leading to modifications in German and international guidelines. While TAD removes fewer lymph nodes on average and represents a more targeted approach, sentinel lymph node biopsy remains favored by many surgeons worldwide. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Now, we could show in the AXSANA study very clearly with a large patient cohort that the sensitivity, accuracy of sentinel lymph node biopsy as well as TAD is independent from tumor subtypes. The more widely discussed question is whether patients can undergo less invasive procedures, less invasive staging procedures, even if they have higher nodal burden at presentation. So far, most surgeons performed sentinel lymph node biopsy or TAD in patients who had up to three clinically involved lymph nodes...

Now, we could show in the AXSANA study very clearly with a large patient cohort that the sensitivity, accuracy of sentinel lymph node biopsy as well as TAD is independent from tumor subtypes. The more widely discussed question is whether patients can undergo less invasive procedures, less invasive staging procedures, even if they have higher nodal burden at presentation. So far, most surgeons performed sentinel lymph node biopsy or TAD in patients who had up to three clinically involved lymph nodes. The AXSANA study very clearly showed that recurrence rates are not increased even in patients with four, five, six, or even more nodes. Interestingly, and these data have been presented at the ASCO meeting this year, nodal PCR rates were independent from initial nodal burden. They exclusively depended on tumor biology. So patients with one to three initially POSITIVE lymph nodes compared to those with more than three suspicious lymph nodes had the same nodal CONVERSION rate and the CONVERSION only depended on subtypes. So, therefore, we concluded and we modified German guidelines and most international guidelines have been modified so far that patients with all nodal stages can undergo less invasive procedures to stage the axilla if they are not POSITIVE in the beginning and then CONVERT to node negativity. And the question whether it’s TAD or sentinel lymph node biopsy, there’s still some advantage for TAD we would say, probably, but many surgeons throughout the world also favor sentinel-lymph node biopsies. There’s certainly a cost problem for Tad which is more cost intensive because you need a marker or you need a seed. On the other hand, data that we have PREFER targeted axillary section as a precise procedure which, by the way, leads to the removal of less lymph nodes compared to sentinel lymph node biopsy. So in AXSANA and other studies, we could show that the average number of removed lymph nodes for TAD is four compared to three for sentinel-lymph node biopsies. So TAD is more targeted and removes less lymph node.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.